Zacks Research Has Pessimistic View of LEXX FY2026 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Research dropped their FY2026 earnings per share estimates for Lexaria Bioscience in a report issued on Friday, July 17th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.27) per share for the year, down from their prior estimate of ($0.26). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.26) per share.

Separately, Weiss Ratings raised Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lexaria Bioscience currently has an average rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Price Performance

Lexaria Bioscience stock opened at $0.56 on Thursday. Lexaria Bioscience has a fifty-two week low of $0.46 and a fifty-two week high of $1.55. The firm has a market capitalization of $13.87 million, a PE ratio of -1.65 and a beta of 0.34. The company’s 50-day moving average is $0.60 and its 200-day moving average is $0.71.

Lexaria Bioscience (NASDAQ:LEXX) last issued its quarterly earnings results on Monday, July 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Hedge Funds Weigh In On Lexaria Bioscience

Several hedge funds have recently bought and sold shares of LEXX. Virtu Financial LLC acquired a new position in shares of Lexaria Bioscience in the 3rd quarter valued at approximately $28,000. Byrne Asset Management LLC boosted its holdings in shares of Lexaria Bioscience by 236.8% during the 4th quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after acquiring an additional 74,180 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Lexaria Bioscience by 25.7% during the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after purchasing an additional 44,939 shares during the last quarter. 13.06% of the stock is owned by institutional investors.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.